Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with allotransplantation.
A new study led by Yale Cancer Center researchers at Yale School of Medicine for the first time analyzed the cost-effectiveness of allotransplantation therapy and gene therapy to help determine equitable treatment options for this historically marginalized pediatric patient population in the United States. First author George Goshua, MD, a member of Yale Cancer Center, will present the findings at the American of Society for Hematology (ASH) Annual Meeting on December 10.
The study used an incremental cost-effectiveness ratio (ICER) to evaluate cost-effectiveness of each therapy. Allotransplantation had an ICER of $138,000 per quality-adjusted life-year (QALY), while gene therapy had an ICER of $253,000.
“While these therapeutic strategies appear to be expensive, and they are, pursuing allotransplantation or gene therapy both meet distributional equity standards in the United States,” said Goshua, who is an assistant professor of medicine (Hematology) at Yale School of Medicine.
Researchers emphasize the importance of considering equity in decision-making for pediatric SCD treatment. “We hope to continue to provide more equity and value-informed transparent benchmarks for stakeholders making crucial funding decisions, and also that other groups join us in doing so,” said Goshua.
On December 7, 2023, Beijing time, NeuExcell Therapeutics announced that its proprietary AAV gene therapy product, NXL-004, designed for treating malignant glioma, has been awarded Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This...
PackGene Biotech Receives Exclusive C+ Round Investment from SDIC Fund, and Hosts a CGT Industry Salon to Discuss Global Strategies
December 1, 2023, PackGene Biotech, a frontrunner in gene therapy delivery, has successfully closed a landmark C+ funding round, securing over 100 million RMB exclusively from SDIC Fund Management Co., Ltd. This funding, a remarkable accomplishment in the current...
Tauopathy’s Role in Aβ Oligomer Formation: New Insights from Transgenic Primate Models on Alzheimer’s Pathogenesis
Tauopathy, characterized by protein tau and Aβ oligomer accumulation, is a significant aspect of Alzheimer's disease. The causal relationship between these accumulations and neurodegeneration remains unclear despite their links to various cognitive and movement...
Huntington's disease (HD) is a devastating neurodegenerative condition caused by a mutation in the Huntingtin gene (HTT). This leads to the production of a mutant form of the huntingtin protein (mHTT) with an extended polyglutamine (polyQ) repeat, which has a...
Plasmid CDMO Services
We provide high quality plasmids that are ideal for any phase of the drug development cycle.
AAV cGMP Manufacturing
AAV Capsid Engineering
Proven technology paving your path to effective therapies for cancer or genetic disorder